| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/09/2010 | CA2150933C Glaucoma treatment |
| 02/04/2010 | WO2010014758A1 Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
| 02/04/2010 | WO2010013849A1 Gpr119 agonist |
| 02/04/2010 | WO2010013836A1 Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition |
| 02/04/2010 | WO2010013815A1 Composition for inhibiting expression of target gene |
| 02/04/2010 | WO2010013805A1 Aminopropylidene derivative |
| 02/04/2010 | WO2010013769A1 Crystal of thiazolidinedione compound, and process for production thereof |
| 02/04/2010 | WO2010013768A1 Crystal of thiazolidinedione compound, and process for production thereof |
| 02/04/2010 | WO2010013640A1 Potentiator of therapeutic efficacy on infectious disease |
| 02/04/2010 | WO2010013633A1 Methods for prediction of rb status and sensitivity to plk1 inhibitor of cell |
| 02/04/2010 | WO2010013595A1 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| 02/04/2010 | WO2010013551A1 Preparation for oral administration comprising water-extracted chondroitin sulfate and quercetin glycoside |
| 02/04/2010 | WO2010013494A1 Pharmaceutical composition comprising botulinum neurotoxin preparation incapable of being synaptically transported, and use thereof |
| 02/04/2010 | WO2010013466A1 Inhibition of replication of hepatitis c virus by cdk inhibitor |
| 02/04/2010 | WO2010013302A1 Spiroaminodihydrothiazine derivative |
| 02/04/2010 | WO2009151590A3 Methods of treating cyp2d6 alternative metabolizers |
| 02/04/2010 | WO2009108760A8 Dendritic macroporous hydrogels prepared by crystal templating |
| 02/04/2010 | US20100029919 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
| 02/04/2010 | US20100029789 Photocrosslinked combination of reactive hyaluronan (e.g., reacted with glycidyl methacrylate) and a hydrophillic polymer or a monomer, particularly an acrylamide derivative; orthopedic implants and spinal disc substitutes |
| 02/04/2010 | US20100029779 Composition and method for treatment of mrsa |
| 02/04/2010 | US20100029766 Blends Comprising a Substituted Fatty Acid or a Derivative Thereof |
| 02/04/2010 | US20100029744 Methods for Alzheimer's Disease Treatment and Cognitive Enhancement |
| 02/04/2010 | US20100029739 Use of a combination of hypothermia inducing drugs |
| 02/04/2010 | US20100029707 Tricyclic compound and medical use thereof |
| 02/04/2010 | US20100029706 HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS |
| 02/04/2010 | US20100029705 Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis |
| 02/04/2010 | US20100029695 Method of treating dermatitis comprising administering a chymase inhibitor |
| 02/04/2010 | US20100029632 improved pharmacokinetics |
| 02/04/2010 | US20100029631 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 02/04/2010 | US20100029603 16alpha-methyl or ethyl substituted estrogens |
| 02/04/2010 | US20100028905 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| 02/04/2010 | US20100028461 Gamma-butyrolactone compound and pharmaceutical composition thereof |
| 02/04/2010 | US20100028444 Use of water-dispersible carotenoid nanoparticles as taste modulators, taste modulators containing water-dispersible carotenoid nanoparticles, and, method for taste modulation |
| 02/04/2010 | US20100028431 Compositions and methods for therapeutic use |
| 02/04/2010 | US20100028412 Transdermal therapeutic system for administering water-soluable active ingredients |
| 02/04/2010 | US20100028387 Biocompatible Coated Nanostructured Titanium Surfaces |
| 02/04/2010 | US20100028385 Treatment of excess cerumen secretion |
| 02/04/2010 | US20100028349 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity |
| 02/04/2010 | US20100028318 Agent for relief or prevention of xerostomia |
| 02/04/2010 | US20100028305 Methods for the treatment of lysosomal storage disorders |
| 02/04/2010 | US20100026235 Charging Control in an Electric Vehicle |
| 02/04/2010 | CA2732282A1 Aminopropylidene derivative |
| 02/04/2010 | CA2731358A1 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
| 02/03/2010 | EP2149563A1 Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound |
| 02/03/2010 | EP2149560A1 1-substituted tetrahydroisoquinoline compound |
| 02/03/2010 | EP2149550A1 Nitrogen-containing five-membered heterocyclic compound |
| 02/03/2010 | EP2148684A2 Method of treating vitamin d insufficiency and deficiency |
| 02/03/2010 | EP1511742B1 Kinase inhibitors |
| 02/03/2010 | EP1421938B1 Antitumor agents and process for producing the same |
| 02/03/2010 | EP1351679B1 Method and composition for the treatment of diabetic neuropathy |
| 02/03/2010 | EP1078636B1 Pharmaceutical composition for use in emergency treatment and preparation method thereof |
| 02/03/2010 | CN101638437A Growth hormone fusion protein |
| 02/02/2010 | US7655797 Intermediates for making 2,4-pyrimidinediamine compounds |
| 02/02/2010 | US7655771 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 02/02/2010 | US7655755 Breast cancer resistance protein (BCRP) and the DNA which encodes it |
| 02/02/2010 | US7655694 Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury |
| 02/02/2010 | US7655680 (E)-3-[2-(3,4-diethoxyphenyl)thiazole-4-yl]-1-(2-methoxyphenyl)propenone; inhibiting the activity of phosphodiesterase 4, the production of tumor necrosis factor alpha, and the production of interleukin 4; atopic dermatitis |
| 02/02/2010 | US7655674 Hedgehog antagonists that inhibit the hedgehog pathway in a smoothened gain-of-function cell with an IC50 within a factor of 20, 10, or even a factor of 5, of the IC50 with which they inhibit the hedgehog pathway in a patched-null cell |
| 02/02/2010 | US7655663 (2S)-4,4-difluoro-1-(2-{[1-(2-pyrazinyl)piperidin-4-yl]amino}acetyl)-2-pyrrolidine carbonitrile; enzyme inhibitors; diabetes |
| 02/02/2010 | US7655661 Prodrugs of CC-1065 analogs |
| 02/02/2010 | US7655660 Antitumor antibiotic; water solubility, stability; N-[2-{(1-chloromethyl)-1,2-dihydro-5-[(4-methylpiperazino)carbonyloxy]-3H-benz(e)indol-3-yl}carbonyl]-1H-indol-5-yl]-5-[(3-methyldithio-1-oxopropyl)-amino]-1H-indole-2-carboxamide |
| 02/02/2010 | US7655654 Tetrazole substituted quinazoline compounds for antiproliferation agents |
| 02/02/2010 | US7655647 3-[(1-oxo-2-cyclopropylmethyl-heptyl)]amino-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; amyloid precursor protein and beta -peptide inhibitor; beta or gamma secretases inhibitor; amyloid plaques and neurofibrillar tangles; neurodegenerative diseases: Alzheimer's disease; Down syndrome |
| 02/02/2010 | US7655637 N-pyrazole A2A receptor agonists |
| 02/02/2010 | US7655633 Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia |
| 02/02/2010 | US7655632 prevention or treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. 4-[(4-{3-[1-carbamoyl-1-(methyl)-ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole |
| 02/02/2010 | US7655628 Method for treating liver cirrhosis or interstitial pulmonary fibrosis |
| 02/02/2010 | US7655624 Peptide and peptide mimetic conjugates with integrin-inhibitor properties |
| 02/02/2010 | US7655619 Insulin-associated peptides with effects on cerebral health |
| 02/02/2010 | US7655616 Traumatic brain and spinal cord injury treatment; administering interleukin-1B converting enzyme (capsase-1) inhibitor |
| 02/02/2010 | US7655460 Nucleic acids encoding sodium channel SCN1A alpha subunit proteins with mutations associated with epilepsy |
| 02/02/2010 | US7655459 Enhancer contains interleukin as an effective component and is co-administered with a recombinant herpes simplex virus that selectively replicates in cancer cells |
| 02/02/2010 | US7655426 Ephrin-B receptor protein involved in carcinoma |
| 02/02/2010 | US7655425 Uses of a chemokine receptor able to bind to MCP-1, MIP-1α and/or RANTES |
| 02/02/2010 | US7655412 Useful to form complexes having an affinity to targets of interest; verotoxin subunit B |
| 02/02/2010 | US7655408 PCA3 messenger RNA species in benign and malignant prostate tissues |
| 02/02/2010 | US7655261 Medicament and method of treatment of patients with heavy metals |
| 02/02/2010 | US7655246 Chlamydia protein, gene sequence and uses thereof |
| 02/02/2010 | US7655239 Peptides for use in diagnosis, prevention and treatment of cell proliferative disorders |
| 02/02/2010 | US7655226 Treatment of Pompe's disease |
| 02/02/2010 | CA2494583C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 02/02/2010 | CA2485685C Calcium receptor modulating agents |
| 02/02/2010 | CA2442478C Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation |
| 02/02/2010 | CA2439051C Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| 02/02/2010 | CA2426043C Modulating angiogenesis |
| 02/02/2010 | CA2418868C 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 02/02/2010 | CA2410305C Preparations comprising combinations of enzyme inhibitors, and the use thereof |
| 02/02/2010 | CA2407428C Hydantoin-containing glucokinase activators |
| 02/02/2010 | CA2401832C 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 02/02/2010 | CA2396158C Dipeptide nitrile cathepsin k inhibitors |
| 02/02/2010 | CA2390858C N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa |
| 02/02/2010 | CA2358581C Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
| 02/02/2010 | CA2324418C Novel opiate compounds, methods of making and methods of use |
| 02/02/2010 | CA2315205C Substituted 2-aryl-4-amino-quinazolines, methods for the prodution ans use thereof as medicaments |
| 02/02/2010 | CA2294809C Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same |
| 02/02/2010 | CA2293724C Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| 02/02/2010 | CA2282842C A method of recovering highly purified vwf or factor viii/vwf-complex |
| 02/02/2010 | CA2180425C Purified primate ctla-8 antigens and related reagents |
| 02/02/2010 | CA2142331C Immunoglobulins devoid of light chains |
| 01/28/2010 | WO2010011349A2 Pyrimidine-2,4-diamine jak2 kinase inhibiting anti-inflammation use |